Web11 apr. 2024 · BOSTON, April 11, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman … Web12 apr. 2024 · Inozyme Pharma is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks. Summary Inozyme Pharma beats RenovoRx on 7 of the ...
Inozyme Pharma (INZY) Earnings Date & Reports - TipRanks
Web27 mrt. 2024 · Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) – Equities researchers at Wedbush upped their Q1 2024 earnings estimates for shares of Inozyme Pharma in a report issued on Wednesday, March 22nd. WebInozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. Benzinga. Why Inozyme Pharma (INZY) ... bisection function
INZY Stock Price Inozyme Pharma Inc. Stock Quote (U.S.: Nasdaq ...
WebYou can buy and sell Inozyme Pharma (INZY) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. … Web13 apr. 2024 · We are developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. View Corporate Presentation Stock Quote Change WebInozyme Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. INZY updated stock price target summary. Dow Jones, a News Corp company About WSJ dark chocolate chunk oatmeal cookies